Celcuity (NASDAQ:CELC) Faces Volatility After Mixed Clinical Trial Data

  • Analyst Craig-Hallum maintains a positive long-term outlook for Celcuity (NASDAQ:CELC), setting a $171 price target despite recent volatility.
  • Celcuity shares experienced a significant 25% drop following mixed results from its critical Phase 3 VIKTORIA-1 clinical trial.
  • The experimental drug gedatolisib demonstrated a median progression-free survival (PFS) of 11.1 months for some patients, with FDA approval anticipated by July 2026.

Celcuity (NASDAQ:CELC) is a clinical-stage biotechnology company. This means it focuses on developing new drugs that are still in the testing phase. Celcuity's main work is in oncology, with a key focus on its experimental drug, gedatolisib, for treating advanced breast cancer.

An analyst from Craig-Hallum has adjusted their outlook on Celcuity, lowering the price target to $171. A price target is an analyst's estimate of a stock's future value. This new target, however, still indicates a potential 91.88% increase from the stock's price of $89.12 at the time of the rating.

Despite the analyst's positive long-term view, Celcuity shares recently fell by over 25%. This significant drop followed the release of data from its Phase 3 VIKTORIA-1 clinical trial. A Phase 3 trial is a critical, late-stage test to confirm a drug's effectiveness and safety before seeking government approval.

The data presented a mixed picture. As highlighted by Reuters, the stock declined because the treatment underperformed results from a previous trial. However, GlobeNewswire reports that the drug, gedatolisib, doubled the likelihood of survival without the disease getting worse compared to current treatments for some patients.

The trial showed a median progression-free survival (PFS) of 11.1 months for patients on a gedatolisib regimen, compared to 5.6 months for those on the current standard care. Progression-free survival measures the time a patient lives with a disease without it worsening. Celcuity expects to seek FDA approval by July 2026.

About the Author
Tony Dante

Market news, earnings, and analyst coverage

Tony Dante writes market news and earnings coverage for the FMP blog, reporting on quarterly results, analyst rating changes, and company developments. His posts turn timely market events into concise, data-backed analysis for readers tracking individual names and sectors.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account